Paper
Glycosylation of therapeutic proteins in different production systems
Published Apr 1, 2007 · R. Werner, K. Kopp, M. Schlueter
Acta Pædiatrica
Q1 SJR score
108
Citations
0
Influential Citations
Abstract
Glycosylation plays an important role in a number of therapeutic proteins, including monoclonal antibodies. The enzymatic activity of a therapeutic protein is mainly determined by the protein structure, whereas the pharmacokinetics, pharmacodistribution, solubility, stability, enhancement of effector function and receptor binding are all influenced by the carbohydrate moiety.
Highly CitedStudy Snapshot
Glycosylation plays a crucial role in therapeutic protein production, influencing pharmacokinetics, pharmacodistribution, solubility, stability, effector function enhancement, and receptor binding.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
Optimization of humanized IgGs in glycoengineered Pichia pastoris
Glycoengineered yeast Pichia pastoris can produce human antibodies with specific human N-glycan structures, optimizing antibody-mediated effector functions for potential therapeutic applications.
2006·412citations·Huijuan Li et al.·Nature Biotechnology
Nature Biotechnology
Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins.
Glycoengineering can enhance therapeutic proteins' activity, half-life, and convenience, improving patient compliance and reducing injection frequency.
2005·441citations·A. Sinclair et al.·Journal of pharmaceutical sciences
Journal of pharmaceutical sciences
Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
Advances in glycoengineering yeasts and humanizing their glycosylation structures show promise for producing human therapeutic proteins, challenging the dominance of mammalian cell culture.
2004·416citations·T. Gerngross·Nature Biotechnology
Nature Biotechnology
Economic aspects of commercial manufacture of biopharmaceuticals.
Process improvements and regulatory changes can lead to significant cost savings and reduced therapeutic doses in biopharmaceutical production.
2004·141citations·R. Werner·Journal of biotechnology
Journal of biotechnology
Structural Requirements for Additional N-Linked Carbohydrate on Recombinant Human Erythropoietin*
N-linked glycosylation in recombinant human erythropoietin is influenced by the structural requirements of the protein, with some regions supporting it more effectively than others, and carbohydrate addition precedes polypeptide folding.
2004·57citations·S. Elliott et al.·Journal of Biological Chemistry
Journal of Biological Chemistry
Citations
Current regulatory requirements for stability studies of biological medicinal products: a review
Special stability testing considerations for various biological medicinal products indicate the need to develop and improve the system of requirements for BMP stability assessment, facilitating optimization of their life cycle in the Russian Federation and other EAEU member states.
2024·0citations·A. Soldatov et al.·Biological Products. Prevention, Diagnosis, Treatment
Biological Products. Prevention, Diagnosis, Treatment
Modifying Naturally Occurring, Nonmammalian-Sourced Biopolymers for Biomedical Applications.
Natural biopolymers from nonmammalian sources offer diverse properties and sustainable sourcing, offering potential for biomedical applications.
2024·1citation·Bryce D Shirk et al.·ACS biomaterials science & engineering
ACS biomaterials science & engineering
Single Cell Expression Systems for the Production of Recombinant Proteins for Immunodiagnosis and Immunoprophylaxis of Toxoplasmosis
Recombinant Toxoplasma gondii antigenic proteins are crucial for accurate disease detection and vaccine development, contributing to improved healthcare outcomes and disease control.
2024·1citation·Karolina Sołowińska et al.·Microorganisms
Microorganisms
Long-Acting Strategies for Antibody Drugs: Structural Modification, Controlling Release, and Changing the Administration Route.
Long-acting antibody drugs can be achieved through structural modification, controlled release, and changing administration routes, with subcutaneous injection of microspheres being a promising option.
2024·1citation·Hao Wang et al.·European journal of drug metabolism and pharmacokinetics
European journal of drug metabolism and pharmacokinetics
Engineered therapeutic proteins for sustained-release drug delivery systems.
Recent advances in structural modifications and controlled-release delivery systems for protein therapeutics show promise in enhancing their stability and effectiveness for various diseases.
2023·18citations·Thoa Thi Kim Nguyen et al.·Acta biomaterialia
Acta biomaterialia